What is Novo Nordisk A/S's current stock price?

Novo Nordisk A/S (NOVO-B.CO) currently trades at DKK 255.25. Track real-time price changes and historical performance on AllInvestView.

What is Novo Nordisk A/S's dividend yield?

Novo Nordisk A/S has a dividend yield of 4.18155800%. The 5-year average dividend yield is 1.93000000%. Track dividend payments and income with AllInvestView.

What sector is Novo Nordisk A/S in?

Novo Nordisk A/S operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

S in new tab

255.25 DKK

Add to portfolio

P/E

9.47

EPS

26.26

Yield

4.18%

Safety Score

P/B

4.98

ROE

59.82

Beta

0.34

Target Price

307.56 DKK

Novo Nordisk A/S

🧾 Earnings Recap – Q3 2025

Novo Nordisk reported robust Q3 2025 results, achieving 15% sales growth and 10% operating profit growth, while narrowing guidance due to anticipated lower growth in GLP-1 diabetes and obesity treatments.

Approved Rybelsus with cardiovascular indications in the U.S. and EU, enhancing portfolio in diabetes care.
Obesity care sales surged 41%, significantly boosted by a 168% increase in Wegovy, underscoring strong demand.
Initiated a company-wide transformation expected to lead to DKK 8 billion in annual savings by 2026, focusing resources on diabetes and obesity.
Operational efficiency improvements are anticipated from the reduction of approximately 9,000 global positions, aiming to enhance shareholder returns.

All NOVO-B.CO earnings recaps View full recap page

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Novo Nordisk A/S (NOVO-B.CO)

Currency: DKK

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Novo Nordisk A/S Analysis (NOVO-B.CO)

Denmark Health Care Official Website Stock

Is Novo Nordisk A/S a good investment? Novo Nordisk A/S (NOVO-B.CO) is currently trading at 255.25 DKK. Market analysts have a consensus price target of 307.56 DKK. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 9.47. This relatively low multiple may signal that Novo Nordisk A/S is undervalued compared to historical market norms.

Earnings Schedule: Novo Nordisk A/S is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is 21.86.

For income investors, Novo Nordisk A/S pays a dividend yield of 4.18%. With a payout ratio of 45%, the dividend appears sustainable.

Investor FAQ

Does Novo Nordisk A/S pay a dividend?

Yes, it pays an annual dividend of 11.70 DKK (4.18% yield).

What asset class is Novo Nordisk A/S?

Novo Nordisk A/S is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of 26.26.

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Exchange Ticker

NOV.DE

NOV.F

CPH (Denmark) NOVO-B.CO

NOV.SG

Trades

Dividend Yield

4.18%

5y avg 1.93%

Annual Dividends

11.70DKK

Next Ex. Div Date

Aug. 14, 2026

Payout Ratio

44.64%

Dividend History paid per year (DKK)

Historical Dividends

Year	Total Dividends
▸2027	12.44 DKK
Aug. 18, 2027 (estimated)	4.0184
March 22, 2027 (estimated)	8.4258
▸2026	11.70 DKK
Aug. 18, 2026	3.7500
March 31, 2026	7.9500
▸2025	11.65 DKK
Aug. 19, 2025	3.7500
April 1, 2025	7.9000
▸2024	9.90 DKK
Aug. 19, 2024	3.5000
March 26, 2024	6.4000
▸2023	14.15 DKK
Aug. 22, 2023	6.0000
March 28, 2023	8.1500
▸2022	11.15 DKK
Aug. 16, 2022	4.2500
March 29, 2022	6.9000
▸2021	9.35 DKK
Aug. 18, 2021	3.5000
March 30, 2021	5.8500
▸2020	8.60 DKK
Aug. 18, 2020	3.2500
March 31, 2020	5.3500
▸2019	8.15 DKK
Aug. 20, 2019	3.0000
March 26, 2019	5.1500
▸2018	7.85 DKK
Aug. 21, 2018	3.0000
March 27, 2018	4.8500
▸2017	7.60 DKK
Aug. 22, 2017	3.0000
March 28, 2017	4.6000
▸2016	9.40 DKK
Aug. 12, 2016	3.0000
March 21, 2016	6.4000
▸2015	5.00 DKK
March 20, 2015	5.0000
▸2014	4.50 DKK
March 21, 2014	4.5000
▸2013	18.00 DKK
March 21, 2013	18.0000
▸2012	14.00 DKK
March 22, 2012	14.0000
▸2011	10.00 DKK
March 24, 2011	10.0000
▸2010	7.50 DKK
March 25, 2010	7.5000
▸2009	6.00 DKK
March 19, 2009	6.0000
▸2008	4.50 DKK
March 13, 2008	4.5000
▸2007	7.00 DKK
March 8, 2007	7.0000
▸2006	6.00 DKK
March 9, 2006	6.0000
▸2005	4.80 DKK
March 10, 2005	4.8000
▸2004	4.40 DKK
March 17, 2004	4.4000
▸2003	3.60 DKK
March 26, 2003	3.6000
▸2002	3.35 DKK
March 13, 2002	3.3500
▸2001	66.25 DKK
March 21, 2001	66.2500

Upcoming Dividends

Name	Payment Date	Status	Amount
Novo Nordisk A/S	Aug 18, 2026	Paid	3.75 DKK
Novo Nordisk A/S	Mar 31, 2026	Paid	7.95 DKK

Stock Splits

Split Date	Split Ratio to 1
June 4, 1991	1.036
Jan. 2, 1997	2:1
April 4, 2001	5:1
Dec. 3, 2007	2:1
Jan. 2, 2014	5:1
Sept. 13, 2023	2:1

Fundamentals

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.

Novo Nordisk A/S NOVO-B.CO · Stock Open Novo Nordisk A/S in new tab

Novo Nordisk A/S

Key Metrics

Growth

Estimates

Dividend

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Novo Nordisk A/S Analysis (NOVO-B.CO)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Novo Nordisk A/S NOVO-B.CO · Stock Open Novo Nordisk A/S in new tab

Key Metrics

Growth

Estimates

Dividend

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Novo Nordisk A/S Analysis (NOVO-B.CO)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications